Prevalence of antibodies against varicella zoster, herpes simplex (types 1 and 2), hepatitis B and hepatitis A viruses among Spanish adolescents

Journal of Infection

Volumn 36, Issue 1, 1998, Pages 53-56

  Gil, A ^a   Gonzalez A ^b   Dal Re R ^b   Ortega, P ^a   Dominguez, V ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

ADOLESCENT; ARTICLE; BLOOD; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A; HEPATITIS B; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNOLOGY; MALE; PREVALENCE; SPAIN;

ADOLESCENT; ANTIBODIES, VIRAL; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A; HEPATITIS B; HERPES SIMPLEX; HERPES ZOSTER; HUMANS; MALE; PREVALENCE; SPAIN;

EID: 0031601037     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(98)93126-7     Document Type: Article

References (21)

1. Alter MJ, Coleman PJ, Alexander J et al. Importance of heterosexual activity in the transmission of hepatitis A and non-A, non-B hepatitis. JAMA 1989; 262: 1201-1205.
2. Hornung CA, Alexander GR, Lee FK, Potts WA, Nahmias AJ. A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection. J Infect Dis 1990; 162: 306-312.
3. Perez-Trallero E, Cilia G, Urbieta M, Dorronsoro M, Otero F, Marimon J. Falling incidence and prevalence of hepatitis A in Northern Spain. Scand J Infect Dis 1994; 26: 133-136.
4. Haake DA, Zakowski PC, Haake DL, Bryson YJ. Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev Infect Dis 1990; 5: 788-798.
5. Hadler SC. Global impact of hepatitis A virus infection changing patterns. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins, 1991: 14-20.
6. Last JM. Guidelines on Ethics for Epidemiologists. Int J Epidemiol 1990; 19: 226-229.
7. Anónimo. Avance del Anuario Estadistico. Madrid: Instituto Nacional de Estadistica, 1994: 200-206.
8. American Academy of Pediatrics, Committee on Infectious Diseases. Recommendation for the use of Live Attenuated Varicella vaccine. Pediatrics 1995; 5: 791-796.
9. Cilia G, Perez-Trallero E, García JM. Seroepidemiology of varicella in children from Spain. J Infect Dis 1987; 156: 851.
10. WHO. Health problem of adolescence. World Health Organization Technical Report Series. Geneva, 1965; No. 308.
11. Miller E, Vurdien J, Farrington P. Shift in the age of chickenpox. Lancet 1993; 341: 308-309.
12. Gray GC, Palinkas LA, Kelly PW. Increasing incidence of varicella hospitalisations in the United States army and navy personnel: are today's teenagers becoming more susceptible? Should recruits be vaccinated? Pediatrics 1990; 86: 867-873.
13. Best JM, Palmer SJ, Hesketh L, Morgan-Capner P, Mathers K. Immunity to viral infections among medical students in London. BMJ 1994; 309: 876.
14. Breining MK, Kingsley LA, Armstrong JA, Freeman DJ, Ho M. Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections. J Infect Dis 1990; 162: 299-305.
15. Langenberg AGM, Burke RL, Suzanne FA et al. A recombinant glycoprotein vaccine for herpes simplex type 2: safety and efficacy. Ann Intern Med 1995; 122: 889-898.
16. Bolumar F, Giner-Durán R, Hernandez-Aguado I, Serra-Desfilis MA, Rebagliato M, Rodrigo JM. Epidemiology of hepatitis A in Valencia, Spain: public health implications. J Vir Hep 1995; 2: 145-149.
17. Salleras L, Bruguera M, Vidai J et al. Prevalence of hepatitis B markers in the population of Catalonia (Spain). Rationale for universal vaccination of adolescents. Eur J Epidemiol 1992; 8: 640-644.
18. Hallauer J. Viral Hepatitis Prevention Board: summary of strategies and recommendations. Vaccine 1995; 13 (Suppl. 1): S61-S63.
19. World Health Organization. Lutte contre l'hepatite A en santé publique: memorandum d'une réunion de l'OMS. Bulletin of the World Health Organization 1995; 73: 157-163.
20. Bruguera M, Bayas JM, Vilella A et al. Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine. Vaccine (in press).
21. García-Corbeira P, Aguilar L, Dal-Ré R et al. Non-recombinant vs. type specific protein HSV-2 assay for seroprevalence studies: which one to choose? [Abstract 299]. 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, September, 1997.